IVF

INVO Fertility, Inc. (INVO Bioscience, Inc.) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2010. INVO Bioscience, Inc. is a development-stage company focused on the INVOcell device and INVO procedure, an alternative infertility treatment designed to be less expensive and simpler than conventional in vitro fertilization (IVF). The company holds CE marking for distribution in the European Economic Area and other international markets but is awaiting FDA clearance for the U.S. market. As of the reporting date, the company had approximately $3,661 in cash and a working capital deficiency of approximately $2.25 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Product revenue decreased 27% to $26,820 compared to $36,815 in Q1 2009. Management attributed this to smaller international shipments as new distributors worked down initial inventory.
• Net Income Turnaround: The company reported a net income of $870,568, a reversal from a net loss of $651,054 in the prior year. This profit was driven primarily by a non-cash gain of approximately $1.35 million from the revaluation of derivative liabilities (convertible notes and warrants), not operational performance.
• Expense Reduction: Selling, general, and administrative expenses dropped significantly to $446,627 from $656,900, due to reduced staff (5 employees vs. 7), lower travel costs, and deferred financing activities.
• Liquidity Deterioration: Cash on hand fell from $79,052 at the end of 2009 to $3,661 at March 31, 2010. The company continues to burn cash, utilizing a $50,000 line of credit and issuing equity to fund operations.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that the company's negative cash flows, recurring losses, and stockholder deficiency raise substantial doubt about its ability to continue as a going concern. Continued operations depend on raising additional capital.
• Capital Needs: Management estimates a monthly burn rate of approximately $175,000. The company is utilizing a Reserve Equity Financing (REF) agreement with AGS Capital Group (up to $10 million) and seeking private placements. If funding is not secured, operations may be curtailed.
• Regulatory Status: While CE marked for international use, the company is awaiting FDA 510(k) clearance for the U.S. market, which requires a clinical trial. Management hopes for clearance by the end of 2011, contingent on funding.
• Legal Proceedings: The company is defending against a lawsuit filed by former employees and a creditor of Medelle Corporation regarding asset transfers. Management believes the claims are without merit and has filed a motion to dismiss.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2010, citing limited resources and a lack of segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to meet its estimated $175,000 monthly operating burn rate given the $3,661 cash balance.
• Derivative Liability Volatility: Confirm the sustainability of the reported net income, which is heavily influenced by non-cash mark-to-market adjustments on convertible notes and warrants.
• Financing Progress: Monitor the status of the AGS Capital REF agreement and any new private placements to ensure the "going concern" risk is mitigated.
• Regulatory Milestones: Track progress on the FDA 510(k) clinical trial and international registration delays that are impacting revenue growth.
• Legal Exposure: Review the outcome of the Medelle Corporation lawsuit to assess potential financial liabilities.